Diagnosesicherheit und Produktivität des Labors steigern – mit den neuen Novocastra HD Antikörpern für die Immunhistochemie (IHC)


Leica Microsystems gibt die Einführung der Novocastra™ HD Antikörper-Palette bekannt, 80 klinisch wichtigen Antikörperklonen für die Immunhistochemie, die 10 Bereiche der anatomischen Pathologie abdecken.

[Translate to german:]

Novocastra HD was developed to meet the needs of pathologists and histologists, in terms of menu, diagnostic confidence and workflow.  This new ‘Highly Definitive’ range was created following extensive global market research on customer preferences, combined with the results of a comprehensive competitive evaluation* of each antibody by NordiQC.  The Novocastra HD menu therefore represents antibodies with independently qualified performance, each available in a range of new sizes and formats aligned to laboratory workloads.

‘When it comes to patient diagnosis, we know that excellence in staining quality isn’t an option - it’s an essential requirement’, says Arnd Kaldowski, President of Leica Biosystems.  ‘We ensured the optimized performance of each and every product and have compared performance on BOND with other leading clones in the market on competitive IHC stainers. The new Novocastra HD range represents our new trusted standard in the selection of high performing antibodies.’

The Novocastra HD range will be available for sale in the USA and EU from August 2012, commencing with the breast pathology menu. Leica Microsystems plans to release a further nine disease specific ranges in 2012 and 2013. 

*Independent evaluation by NordiQC according to the manufacturers‘ instructions for use, commissioned by Leica Microsystems